A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer

NCT01276548 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC
DRUG: Genexol® 175mg/m2 plus Carboplatin 5 AUC

Sponsor

Samyang Biopharmaceuticals Corporation